How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fundaci-n-p-blica-andaluza-para-la-investigaci-n-de-m-laga-en-biomedicina-y-salu.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud pipeline: 6 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Experimental: RAL QD	Experimental: RAL QD	marketed
Prednisone withdrawal	Prednisone withdrawal	marketed
Prednisone continuation	Prednisone continuation	marketed	Corticosteroid	Glucocorticoid receptor	Immunology
Humalog Kwikpen	Humalog Kwikpen	marketed	Rapid-acting insulin analog	Insulin receptor	Diabetes
Toujeo SoloStar	Toujeo SoloStar	marketed	Long-acting basal insulin	Insulin receptor	Diabetes
Active comparator: DRV/cb	Active comparator: DRV/cb	marketed	HIV protease inhibitor with pharmacokinetic booster	HIV protease	Infectious Disease
Metformin + Testosterone Undecanoate	Metformin + Testosterone Undecanoate	phase 3	Combination therapy: biguanide + androgen replacement	AMPK (metformin); androgen receptor (testosterone undecanoate)	Endocrinology / Metabolic Disease

Therapeutic area mix

Diabetes · 2
Endocrinology / Metabolic Disease · 1
Immunology · 1
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sanofi · 3 shared drug classes
Eli Lilly and Company · 2 shared drug classes
Novo Nordisk A/S · 2 shared drug classes
ANI Pharmaceuticals · 1 shared drug class
Allergan · 1 shared drug class
Aramis Biosciences, Inc. · 1 shared drug class
Acrotech Biopharma Inc. · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud:

Cite this brief

Drug Landscape (2026). Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-n-p-blica-andaluza-para-la-investigaci-n-de-m-laga-en-biomedicina-y-salu. Accessed 2026-05-17.